Maxiflo 100 Rotacap is a combination inhalation medication containing Formoterol fumarate dihydrate (6 mcg) and Fluticasone Propionate (100 mcg) per dose, indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Formoterol is a long-acting beta2-adrenergic agonist (LABA) that provides bronchodilation by relaxing airway smooth muscle, resulting in improved airflow and symptom control. Fluticasone Propionate is a corticosteroid with potent anti-inflammatory properties that reduce airway inflammation, edema, and mucus production, thereby decreasing the frequency and severity of exacerbations. Maxiflo 100 Rotacap is administered via a dry powder inhaler, ensuring targeted delivery to the lungs with rapid onset of action and sustained therapeutic effects. This combination therapy is recommended for patients inadequately controlled on inhaled corticosteroids alone or those requiring both bronchodilation and anti-inflammatory treatment. It is essential to use Maxiflo 100 Rotacap regularly as prescribed to achieve optimal control of respiratory symptoms and prevent disease progression. Common adverse effects may include oral candidiasis, hoarseness, and throat irritation; therefore, patients should be advised to rinse their mouth after inhalation. Maxiflo 100 Rotacap should be used with caution in patients with cardiovascular disorders and monitored for potential systemic corticosteroid effects.